Tag Archives: KIT

Sitravatinib plus nivolumab in NSCLC

Sitravatinib (MGCD516) is an oral multi-tyrosine kinase inhibitor being developed by Mirati Therapeutics. Last week, the company announced that three of eleven patients with non-small cell lung cancer (NSCLC) with genetic alterations in MET, AXL, RET, TRK, DDR2, KDR, PDGFRA, KIT or CBL who were resistant to checkpoint [anti PD-(L)1 therapy] had confirmed partial responses; because of this, dosing in the 34-patient expansion cohort will proceed. Continue reading

Argos’ Metastatic Renal Cell Carcinoma Study Passes Independent Data Safety Monitoring Committee Second Interim Analysis

An independent data monitoring committee (IDMC) has recommended the continuation of Argos’ pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee’s second planned interim data analysis. The next planned interim analysis will be in 6 months. Continue reading

Genspera G-202 – anti-cancer hand grenade

Genspera is a company developing novel prodrugs for the treatment of cancer.  In a phase 2 study in patients with hepatocellular carcinoma who have failed treatment with Nexavar (sorafenib), a tyrosine kinase inhibitor that blocks KIT, FLT-3 RET, raf, VEGFR1-3, and PDGF kinases, a doubling of time to progression was seen in patients taking G-202. Continue reading